Breakthrough Treatment Helps Food Allergy Sufferers Tolerate More Allergens

The high rate of side effects from oral immunotherapy in the NIH trial explains the superiority of omalizumab. A clinical trial found that omalizumab (Xolair) was more effective than oral immunotherapy (OIT) in treating multi-food allergies, particularly in individuals who react to very small amounts of common food allergens. OIT, the standard food allergy treatment [...]

from SciTechDaily https://ift.tt/ladiqwP